INTERNATIONAL
Britain would face 100% tariff on pharmaceuticals under latest Trump plan, sources say
US President Donald Trump's 100% drug tariff targets firms without US factories while exempting EU and Japan but leaves Britain exposed to higher costs. - REUTERS
WASHINGTON: Britain would face 100% tariffs on pharmaceuticals imported into the U.S. under President Donald Trump's latest plan, sources told Reuters on Friday.
AI Brief
Trump announced on Thursday that he was imposing a 100% tariff that would apply to firms unless they build a manufacturing presence in the United States.
The European Union and Japan are exempt from Trump's latest tariff threat because both negotiated trade deals that capped pharmaceutical duties at 15%, Reuters previously reported.
Britain was the first nation to strike a trade deal with Trump, but the pharmaceutical rate remains under negotiation, so Britain is not shielded from the new tariffs, a source told Reuters on Friday.
Trump has framed the move as part of a broader push to onshore drug production and reduce reliance on foreign supply chains, a priority of his administration’s trade and industrial policy.
Pharmaceutical imports from Britain accounted for about 3.3% of total pharmaceutical imports to the U.S. in 2024, according to U.S. trade data.
Your gateway to global news, insights, and stories that matter.
AI Brief
- Trump announced a 100% tariff on pharmaceuticals unless companies build manufacturing facilities in the US.
- EU and Japan are exempt due to existing deals; Britain is not yet protected as its drug tariff terms are still under negotiation.
- The move is part of Trump's strategy to reduce reliance on foreign drug supply chains and boost domestic production.
Trump announced on Thursday that he was imposing a 100% tariff that would apply to firms unless they build a manufacturing presence in the United States.
The European Union and Japan are exempt from Trump's latest tariff threat because both negotiated trade deals that capped pharmaceutical duties at 15%, Reuters previously reported.
Britain was the first nation to strike a trade deal with Trump, but the pharmaceutical rate remains under negotiation, so Britain is not shielded from the new tariffs, a source told Reuters on Friday.
Trump has framed the move as part of a broader push to onshore drug production and reduce reliance on foreign supply chains, a priority of his administration’s trade and industrial policy.
Pharmaceutical imports from Britain accounted for about 3.3% of total pharmaceutical imports to the U.S. in 2024, according to U.S. trade data.